leflunomide has been researched along with Sarcoidosis, Pulmonary in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Sarcoidosis, Pulmonary: Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 7.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 3.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Au, S | 1 |
| Mirsaeidi, M | 1 |
| Aronson, IK | 1 |
| Sweiss, NJ | 2 |
| Sahoo, DH | 1 |
| Bandyopadhyay, D | 1 |
| Xu, M | 1 |
| Pearson, K | 1 |
| Parambil, JG | 1 |
| Lazar, CA | 1 |
| Chapman, JT | 1 |
| Culver, DA | 1 |
| Baughman, RP | 1 |
| Nunes, H | 1 |
| Lower, EE | 1 |
| Sugiyama, Y | 1 |
| Chida, K | 1 |
| Ogura, T | 1 |
| Yamaguchi, T | 1 |
| Miyazaki, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endobronchial Mucosal Biopsy in Patients With Suspected Pulmonary Sarcoidosis[NCT04904939] | 20 participants (Actual) | Interventional | 2020-05-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for leflunomide and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Established and experimental medical therapy of pulmonary sarcoidosis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Clinical Trials | 2013 |
3 other studies available for leflunomide and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.
Topics: Adalimumab; Biopsy; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Middle Aged; | 2014 |
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis.
Topics: Adjuvants, Immunologic; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Sarcoidosis; Sar | 2011 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomid | 2006 |